美国银行因 Skyrizi 表现强劲上调艾伯维 (ABBV) 评级及目标价

On April 30, Bank of America analyst Tim Anderson upgraded AbbVie Inc. (NYSE:ABBV) to Buy from Neutral. It also lifted the price target on the stock to $234 from $226. The firm believes concerns around competitive erosion in the key immunology segment are “overdone.” It points to strong forward indicators for Skyrizi and says new competitors appear to be “category expanding.

该内容为新闻快讯，正文已简化。